Detalles de la búsqueda
1.
Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
J Clin Psychopharmacol
; 34(1): 30-5, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24135840
2.
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
BMC Psychiatry
; 13: 261, 2013 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-24131801
3.
A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.
Clin Schizophr Relat Psychoses
; 10(4): 211-221, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-24846880
4.
Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
J Med Econ
; 16(4): 522-8, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23360177
5.
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
J Clin Psychiatry
; 68(5): 662-8, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17503974
Resultados
1 -
5
de 5
1
Próxima >
>>